About Us Services Careers FAQ Contact Us 0
Home Biotechnology Biologics Contract Development and Manufacturing Organization (CDMO) Market Size to Grow b
Biologics Contract Development and Manufacturing Organization (CDMO) Market

Biologics Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Trends Analysis Report By Type (Mammalian, Non-mammalian (Microbial)), By Product Type (Biologics, Biosimilars) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRBI55200DR
Last Updated : November 21, 2023
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Mammalian
        1. By Value
      3. Non-mammalian (Microbial)
        1. By Value
    3. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Biologics
        1. By Value
      3. Biosimilars
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Mammalian
        1. By Value
      3. Non-mammalian (Microbial)
        1. By Value
    3. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Biologics
        1. By Value
      3. Biosimilars
        1. By Value
    4. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Mammalian
          1. By Value
        3. Non-mammalian (Microbial)
          1. By Value
      2. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Biologics
          1. By Value
        3. Biosimilars
          1. By Value
    5. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Mammalian
        1. By Value
      3. Non-mammalian (Microbial)
        1. By Value
    3. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Biologics
        1. By Value
      3. Biosimilars
        1. By Value
    4. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Mammalian
          1. By Value
        3. Non-mammalian (Microbial)
          1. By Value
      2. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Biologics
          1. By Value
        3. Biosimilars
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Mammalian
        1. By Value
      3. Non-mammalian (Microbial)
        1. By Value
    3. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Biologics
        1. By Value
      3. Biosimilars
        1. By Value
    4. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Mammalian
          1. By Value
        3. Non-mammalian (Microbial)
          1. By Value
      2. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Biologics
          1. By Value
        3. Biosimilars
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Singapore
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Mammalian
        1. By Value
      3. Non-mammalian (Microbial)
        1. By Value
    3. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Biologics
        1. By Value
      3. Biosimilars
        1. By Value
    4. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Mammalian
          1. By Value
        3. Non-mammalian (Microbial)
          1. By Value
      2. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Biologics
          1. By Value
        3. Biosimilars
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Mammalian
        1. By Value
      3. Non-mammalian (Microbial)
        1. By Value
    3. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Biologics
        1. By Value
      3. Biosimilars
        1. By Value
    4. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Mammalian
          1. By Value
        3. Non-mammalian (Microbial)
          1. By Value
      2. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Biologics
          1. By Value
        3. Biosimilars
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Biologics Contract Development and Manufacturing Organization (CDMO) Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Catalent
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Boehringer Ingelheim Group
    3. JRS Pharma
    4. Toyobo Co. Ltd
    5. Parexel International Corp.
    6. Binex Co. Ltd
    7. Lonza Group
    8. Fujifilm Diosynth Biotechnologies USA Inc.
    9. Samsung Biologics
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global healthcare contract development and manufacturing organization market size was valued at USD 221.97 billion in 2021. It is projected to reach USD 476.55 billion by 2030, growing at a CAGR of 8.86% during the forecast period (2022–203
Buy Now
Global Report
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Size The global pharmaceutical contract development and manufacturing organization (CDMO) market size was valued at USD 200.9 billion in 2024 and it is p
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.